Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference
Surrozen, a clinical-stage biotechnology company, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 7:30 a.m. Pacific time. The presentation will focus on their innovative therapies targeting the Wnt pathway for tissue repair and regeneration. A live audio webcast will be available on Surrozen's Investor Relations website. Surrozen aims to address diseases like inflammatory bowel disease and certain neurological disorders through its targeted therapies.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, will present on January 12, 2023 at 7:30 a.m. Pacific time at the 41st Annual J.P. Morgan Healthcare Conference.
A live audio webcast of the presentation will be accessible through Surrozen’s Investor Relations website at investors.surrozen.com. An archived edition of the session will be available later that day.
About Surrozen
Surrozen is a clinical stage biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including inflammatory bowel disease, hepatitis, eye diseases, hearing loss, lung and airway diseases, and certain neurological disorders. For more information, please visit surrozen.com.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen’s discovery, research and development activities, in particular its development plans for its product candidates SZN-1326, SZN-043, and SZN-413, including anticipated clinical development timelines, and the potential for such product candidates to be used to treat human disease. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical or and clinical trials with respect to SZN-1326, SZN-043, SZN-413 and potential future drug candidates, including whether clinical trials for SZN-1326 will be resumed; our ability to fund our clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen’s ability to identify, develop and commercialize drug candidates; Surrozen’s ability to successfully complete preclinical and clinical studies for SZN-1326, SZN-043, SZN-413, or other future product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions, which may be adversely affected by the conflict between Russia and Ukraine; the ongoing coronavirus (COVID-19) pandemic; and all other factors discussed in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 under the heading “Risk Factors,” our Annual Report on Form 10-K for the year ended December 31, 2021 and other documents Surrozen has filed, or will file, with the Securities and Exchange Commission. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen’s expectations, plans, or forecasts of future events and views as of the date of this press release. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen’s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Media Contact:
Evoke Canale
Ian Stone, Managing Director
Tel.: (619) 518-3518
Email: ian.stone@canalecomm.com
Investor Contact:
Investorinfo@surrozen.com
FAQ
When will Surrozen present at the J.P. Morgan Healthcare Conference?
What is the main focus of Surrozen's presentation?
Where can I listen to Surrozen's presentation?
What diseases does Surrozen's therapy aim to address?
What is the stock symbol for Surrozen?
